Sarah Bernier

Discussions on measures to support the competitiveness of the Canadian aluminum industry in the current trade climate. Propose changes to the Clean Technology Investment Tax Credit to support green transition projects in the manufacturing sector. Promouvoir le développement de nouvelles technologies de production d'aluminium au Canada. Discussion on the design of potential future carbon border adjustment mechanism in Canada. Discussion on CUSMA implementation and impacts of trade barriers (ie 232 tariffs) for market access to the US of Canadian aluminum Démarche avec le Fonds Stratégique pour l’Innovation concernant le projet de technologie avancée de fusion d’aluminium. Demande de financement pour le développement de nouvelles technologies de production d'aluminium au Canada. Sources de financement à déterminer.

Representations to inform the government of opportunities for new aluminum production technologies that could be developed in Canada through the Strategic Innovation Fund. Meetings with the federal government on the various trade agreements (North American Free Trade Agreement, Canada-China bilateral trade)

Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments. The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada. Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally. Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic. Public policy issues related to Health Canada's review of NCE Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry. Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada. Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices. National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians. Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process. Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage. Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Vaccine Funding - National Immunization Strategy - maintain federal leadership in providing provinces with funding for new vaccines VACCINE CONTRACTING AND SUPPLY to support the implementation of the federal biomanufacturing strategy, regulation of vaccines for Canadians, address immunization gaps, provide updated and timely information about vaccine development pipeline, support procurement of vaccines SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantage RESEARCH & DEVELOPMENT (R&D) to ensure Canadian capacity in key sectors including biomanufacturing, life sciences, and biotechnology. REGULATORY APPROVAL PROCESS FOR PLANTS WITH NOVEL TRAITS as NOVEL FOODS or INDUSTRIAL BIO_PRODUCTS in respect of an efficient science-based approach and allows for greater cooperation among and between government departments PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases NOVEL FOODS in respect of maintaining a science-based regulatory system for novel foods derived from plant and animal biotechnology INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations) IMPROVEMENTS TO THE Scientifc Research & Experimental Development TAX CREDITS FOOD LABELLING in respect of mitigating the unnecessary introduction of new labelling requirements for products already approved under current regulated process and in respect of maintaining harmonization of requirements with trading nations FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies Establish accountability with the federally established Canadian Drug Agency (formerly Canadian Agency for Drugs and Technologies and Health) (CADTH) and its Common Drug Review process (Health Canada) Creation of a modern policy environment that recognizes international standards and reviews, and establishes clarity on data ownership for intellectual property Clarify the administration of SR&ED program to ensure clinical trials and international research conducted in Canada qualifies as eligible expenses CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologies BIOSAFETY PROTOCOL in respect of Canada's participation in global discussions to ensure an enabling environment for safe new technologies ADVENTITIOUS PRESCENCE POLICY in respect of new agricultural biotechnology products ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty

Trade Policy -- Special Import Measures Act (SIMA) and Possible new policies or regulations, and international negotiations, affecting Canada's international trade regime and consequences for the steel industry. Fiscal, program, policies, and other measures important to the Canadian manufacturing sector's international competitiveness, trade policies, innovation, including investment support for the steel sector. Federal Budgets as they relate to the steel sector, including measures associated with economic development, industrial competitiveness, innovation, and improving the climate for investment, including tax incentives. Climate change and air pollutant policies and regulations, particularly the development of government regulations pursuant to the Canadian Environmental Protection Act, in relation to climate change/greenhouse gas emissions and air pollutant regulations for industrial sectors. Regulations regarding the management and shipment of waste materials, including the transportation of dangerous goods. Programs and/or fiscal measures to support industrial workforce skills developmant

Seeking funding support for genomics and related sciences research in Canada through the financing of Genome Canada's activities.

Input on tax policy as it relates to mining in Canada, innovation in mining, such as Scientific Research & Economic Development Tax Credits, and other tax policy matters impacting the mining industry. Input on red tape reduction items, such as CFIA bulk labelling requirements, and environmental or regulatory permitting requirements for mining and related supply chain infrastructure. Input on transportation infrastructure and improvements, and trade-enabling infrastructure to the benefit of Canadian exporters. Input on policy and recommendations related to mining, critical minerals, and natural resources, including the Canadian Minerals and Metals Plan. Input on economic policy and growth for Canada and Canadian exports Input on climate change and green house gas emissions reduction policy, including the Greenhouse Gas Pollution Pricing Act, Output-Based Pricing System. Input on Clean Fuel Standard regulations under the Canadian Environmental Protection Act, 1999. Input on Clean Electricity Regulations